G T Prince

Learn More
(ibrutinib) or PI3Kd inhibitor (CAL-101) results in increased resistance to antitumor activity of anti-CD20 mAbs. Current study demonstrates that BCR inhibitors strongly down-regulate CD20 expression in tumor cells, leading to decreased binding of anti-CD20 mAbs to the surface of tumor cells and impairment of CDC and ADCC mechanisms that mediate antitumor(More)
The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy in adult chronic phase chronic myeloid leukemia patients (CML-CP) with suboptimal responses to imatinib mesylate. Using(More)
  • 1